Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Altace New Indications, Line Extensions Top King R&D Pipeline

Executive Summary

New indications for the ACE inhibitor Altace top the list of pipeline projects being developed by King to fuel future growth, the company said during an investor presentation April 12

You may also be interested in...



King Defense Against Generic ACE Inhibitors May Include Increased Spending

King will consider increasing marketing spend behind Altace (ramipril) in the second half of the year to strengthen the drug's position against generics of other angiotension converting enzyme inhibitors, CEO Brian Markison said during an Aug. 9 earnings call

King Defense Against Generic ACE Inhibitors May Include Increased Spending

King will consider increasing marketing spend behind Altace (ramipril) in the second half of the year to strengthen the drug's position against generics of other angiotension converting enzyme inhibitors, CEO Brian Markison said during an Aug. 9 earnings call

King Says It Can Grow On Its Own Following Collapse Of Mylan Merger Plans

King will not pursue a new merger partner following the collapse of its proposed agreement to be acquired by Mylan

Topics

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel